Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.

Autor: Meyer PF; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Ashton NJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK., Karikari TK; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South London & Maudsley NHS Foundation, London, UK., Strikwerda-Brown C; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Köbe T; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Gonneaud J; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Pichet Binette A; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada.; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.; McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada., Ozlen H; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Yakoub Y; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Simrén J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Pannee J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Lantero-Rodriguez J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Labonté A; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada., Baker SL; Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA., Schöll M; Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden., Vanmechelen E; ADx NeuroSciences, Ghent, Belgium., Breitner JCS; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada.; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.; McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.; UK Dementia Research Institute at UCL, London, UK., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Poirier J; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada.; Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Villeneuve S; Douglas Mental Health University Institute, Centre for Studies on Prevention of Alzheimer's Disease (StoP-AD), Montreal, Quebec, Canada.; Department of Psychiatry, McGill University, Montreal, Quebec, Canada.; McGill Centre for Integrative Neuroscience, McGill University, Montreal, Quebec, Canada.; Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.

Publikováno v: Annals of neurology [Ann Neurol] 2022 Apr; Vol. 91 (4), pp. 548-560. Date of Electronic Publication: 2022 Feb 18.

Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases.

Autor: Brinkmalm A; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Portelius E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Brinkmalm G; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Pannee J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Dahlén R; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden., Gobom J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden., Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK.; UK Dementia Research Institute at UCL, London, UK.

Publikováno v: Journal of neurochemistry [J Neurochem] 2019 Nov; Vol. 151 (4), pp. 417-434. Date of Electronic Publication: 2018 Nov 12.

Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype.

Autor: O'Connor A; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK., Pannee J; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S-431 80 Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden., Poole T; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK., Arber C; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK., Portelius E; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S-431 80 Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden., Swift IJ; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK., Heslegrave AJ; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK., Abel E; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK., Willumsen N; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK., Rice H; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK., Weston PSJ; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK., Ryan NS; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK., Polke JM; Neurogenetics Laboratory, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK., Nicholas JM; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK., Mead S; National Prion Clinic, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK.; MRC Prion Unit at UCL, UCL Institute of Prion Diseases, 33 Cleveland Street, London W1W 7FF, UK., Wray S; Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK., Chávez-Gutiérrez L; VIB-KU Leuven Center for Brain and Disease Research, 3000 Leuven, Belgium.; Department of Neurosciences, Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven, 3000 Leuven, Belgium., Frost C; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK., Blennow K; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S-431 80 Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden., Zetterberg H; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, S-431 80 Mölndal, Sweden.; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden., Fox NC; Dementia Research Centre, UCL Queen Square Institute of Neurology, London, WC1N 3BG, UK.; UK Dementia Research Institute at UCL, London, WC1E 6AU, UK.

Publikováno v: Brain : a journal of neurology [Brain] 2021 Nov 29; Vol. 144 (10), pp. 2964-2970.

Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study

Autor: Leuzy, A, Chiotis, K, Hasselbalch, SG, Rinne, JO, de Mendonca, A, Otto, M, Lleo, A, Castelo-Branco, M, Santana, I, Johansson, J, Anderl-Straub, S, von Arnim, CAF, Beer, A, Blesa, R, Fortea, J, Herukka, SK, Portelius, E, Pannee, J, Zetterberg, H, Blennow, K, Nordberg, A

Publikováno v: BRAIN
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

The aim of this study was to assess the agreement between data on cerebral amyloidosis, derived using Pittsburgh compound B positron emission tomography and (i) multi-laboratory INNOTEST enzyme linked immunosorbent assay derived cerebrospinal fluid c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2353f3368be6838fb86aa44c0efa2487
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7101

The early diagnosis of Alzheimer's disease: Blood‐based panel biomarker discovery by proteomics and metabolomics.

Autor: Dong, Yun¹ (AUTHOR) dongyun@sztu.edu.cn, Song, Xun¹ (AUTHOR), Wang, Xiao² (AUTHOR), Wang, Shaoxiang³ (AUTHOR), He, Zhendan¹ (AUTHOR) hezhendan@sztu.edu.cn

Publikováno v: CNS Neuroscience & Therapeutics. Nov2024, Vol. 30 Issue 11, p1-20. 20p.